TheStreet.com Stocks Under $10

A Pair of Updates

twocents@thestreet.com (David Peltier) — Mon, 23 Nov 2009 17:28 GMT

Two model portfolio names are in the news today amid chatter on an obesity-drug study and a takeout rumor.

Stocks Under $10 Weekly Summary

twocents@thestreet.com (David Peltier) — Fri, 20 Nov 2009 21:54 GMT

We put some cash to work this week as the model portfolio's benchmark, the Russell 2000, fell for four straight days.

Buying on Weakness

twocents@thestreet.com (David Peltier) — Fri, 20 Nov 2009 15:58 GMT

Adding to our position and upgrading our rating as we believe the company will rebound in the current period.

Poised for a Purchase

twocents@thestreet.com (David Peltier) — Thu, 19 Nov 2009 16:59 GMT

This pharmaceutical name is trading lower on the session, but we will continue to monitor the price action before taking action.

Names on Our Radar

twocents@thestreet.com (David Peltier) — Thu, 19 Nov 2009 16:14 GMT

Here's an update on some of the companies we've been researching since the end of earnings season.

A Robust Update

twocents@thestreet.com (David Peltier) — Wed, 18 Nov 2009 14:18 GMT

Shares of this recent model portfolio addition are surging on strong trial results for its erectile dysfunction drug.

Making Headlines

twocents@thestreet.com (David Peltier) — Tue, 17 Nov 2009 15:29 GMT

This Two-rated model portfolio holding was all over the news last night. Here's an update and our take on the action.

Stocks Under $10 Weekly Summary

twocents@thestreet.com (David Peltier) — Fri, 13 Nov 2009 21:38 GMT

We took advantage of the relative weakness in the small-cap universe to add two new names to the model portfolio this week.

Salvaging a New Name

twocents@thestreet.com (David Peltier) — Thu, 12 Nov 2009 20:03 GMT

Initiating a position in this undervalued scrap metal recycling company, which is seeing a return to profitability.

A Promising Outlook

twocents@thestreet.com (David Peltier) — Wed, 11 Nov 2009 15:43 GMT

This model portfolio name has continued its upward momentum. Here's our forecast for its future.

Weighing In on a New Name

twocents@thestreet.com (David Peltier) — Tue, 10 Nov 2009 18:28 GMT

Despite the risky nature of the biotech sector, this company has the potential to be a Game Breaker.

Reviewing the Numbers

twocents@thestreet.com (David Peltier) — Tue, 10 Nov 2009 14:41 GMT

This model portfolio name announced better-than-expected results overnight. Here's our take ahead of the call.

Ringing the Register

twocents@thestreet.com (David Peltier) — Mon, 09 Nov 2009 17:12 GMT

Spot gold prices reached another new record this morning, making this a good time to take some profits in this name.

Earnings in the Spotlight

twocents@thestreet.com (David Peltier) — Mon, 09 Nov 2009 15:11 GMT

Looking for strong results overall when this Three-rated model portfolio name reports after the close.

Stocks Under $10 Weekly Summary

twocents@thestreet.com (David Peltier) — Fri, 06 Nov 2009 22:36 GMT

This week largely marked the end of earnings season for the model portfolio, leaving us more time to research new names.

Another Earnings Roundup

twocents@thestreet.com (David Peltier) — Thu, 05 Nov 2009 15:41 GMT

Results were mixed for one name, while another beat expectations.

Better-Than-Expected Earnings

twocents@thestreet.com (David Peltier) — Thu, 05 Nov 2009 15:09 GMT

These two names announced results that exceeded consensus analyst estimates. Here's a look at the details.

A Quartet of Previews

twocents@thestreet.com (David Peltier) — Wed, 04 Nov 2009 17:22 GMT

Here's what we'll be listening for when four of our model portfolio names report earnings before the open on Thursday.

Adding Shares

twocents@thestreet.com (David Peltier) — Wed, 04 Nov 2009 15:20 GMT

These two model portfolio names have reported earnings, and we're increasing our stake in one of them.

Mixed Earnings Results

twocents@thestreet.com (David Peltier) — Wed, 04 Nov 2009 14:52 GMT

Here's a look at two model portfolio names that announced third-quarter numbers overnight.